TrialOrphanet journal of rare diseases2012

Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies.

Dominique P Germain et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.